BRAF and colonic neoplasm: Especially in the P53 knock-out subclone of the BRAFV600E-mutated colon carcinoma model RKO (RKOp53KO), the ETS factor inhibitor was already active in a nanomolar range (Figure 1A,B), while the effect was distinctly weaker in the BRAF wild-type HCT116 colon cancer model (Supplementary Figure S1C,D).